We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topics
- Shortages and supply disruptions (21)
- Safety monitoring and information (13)
- Manufacturing (7)
- Compliance and enforcement (6)
- Labelling and packaging (4)
- Import and export (3)
- Scheduling (national classification system) (3)
- Committees and advisory bodies (2)
- Legislation (2)
- Advertising (1)
- Clinical trials (1)
- Fees and payments (1)
- Medicinal cannabis hub (1)
Collection content
113 result(s) found, displaying 11 to 20
-
PageInformation on proposing a new ingredient name to be included on the approved list.
-
PageGLP-1 receptor agonists such as Ozempic (semaglutide) and its derivatives are regulated as prescription-only medicines.
-
PageApplications for extension of indications to align with a reference product can be submitted via the Variation e-form. This electronic form is available through the TBS portal.
-
PageFind out about the discontinuation of Protaphane InnoLet insulin cartridges and the substitute product available.
-
GuidanceGuidance to help sponsors and manufacturers of medicines meet the Australian labelling requirements in TGO 91 and TGO 92.
-
GuidanceGuidance on how to apply to register a biosimilar medicine on the Australian Register of Therapeutic Goods (ARTG) and ongoing sponsor responsibilities.
-
GuidanceGuidance for sponsors on the fees payable and timeframes for different types of prescription medicine applications.
-
GuidanceGuidance to assist sponsors and manufacturers comply with Therapeutic Goods (Microbiological standards for medicines) (TGO 100) Order 2018.
-
GuidanceGuidance on requirements relating to impurities in prescription medicines entered in the Australian Register of Therapeutic Goods (ARTG).
-
GuidanceGuidance on when and how to provide Product Information to us.